Microbiome Clinical Studies Loom Large In 2018
Executive Summary
Events are moving fast in the microbiome field. The sector is expecting results from numerous initial clinical studies during 2018, from across a spectrum of approaches and mechanisms of action, which could lead to new rounds of financings and M&A activity.
You may also be interested in...
GI Innovation CEO On Developing World’s First Microbiome-Biologics Combo
With an ultimate goal to develop the world’s first microbiome and protein drug combination therapies using its platform technology, GI Innovation is rapidly progressing its protein drug pipeline in allergic diseases and cancer on the back of its expert teams and external partnerships, the South Korean bioventure’s CEO tells Scrip.
Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019
Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.
Full Steam Ahead At Ferring To Unlock Microbiome Potential For Reproduction
The Swiss group is expanding its alliance with the Karolinska Institutet to conduct 10 studies designed to improve understanding of the microbiome’s impact on reproductive and gut health challenges.